In The Press

January, 2019 Alopexx Vaccine Announces Licensing Agreement with Merck Animal Health
April, 2018 Alopexx Pharmaceuticals’ F598 Monoclonal Antibody Binds to poly-N-acetylglucosamine (PNAG) on Microbial Surfaces Offering Potential Protective Immunity Against Multiple Pathogens
October, 2017 Alopexx completes first-in-man trial of its novel, broad- spectrum anti-microbial vaccine
September, 2017 Valerion Presents Preclinical Proof-of-Concept Data for VAL-0417 for the Treatment of Lafora Disease
August, 2017 Valerion: World Pharma Today
July, 2017 Valerion Initiates VAL-1221 Dosing in Patients with Pompe Disease
March, 2017 Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease
December, 2016 Alopexx Oncology presents encouraging results of a Phase 1 study of DI-LEU16-IL2 in relapsed/refractory NHL at the American Society of Hematology Annual Meeting
December, 2015 An Eye on Alzheimers
December, 2015 Alopexx Oncology Presents Encouraging Phase I/II Clinical Data On DI-Leu16-IL2 At The American Society Of Hematology Annual Meeting
September, 2015 Valerion Therapeutics Announces Positive Results Of Non-Clinical Research Study at SSIEM Annual Symposium
August, 2015 Alopexx Pharmaceuticals and Vaccine Highlighted as novel treatments of Super Bugs
May, 2015 “2015 World Medical Innovation Forum” cites “Early Diagnosis and Treatment of Alzheimer’s Disease” as the top field where breakthroughs will be made
December, 2014 Cognoptix Expands Clinical Advisory Board
December, 2014 Catalent And Valerion Therapeutics Collaborate To Bring New Treatments For Orphan Genetic Disorders To Market
September, 2014 Cognoptix raises over $15 million to fund pivotal clinical trial and final product development of eye test designed to identify early-stage Alzheimer’s Disease
February, 2014 Cognoptix Eye Test Generates Robust Results in Clinical Study to Identify Alzheimer’s Disease
April, 2013 4s3 Bioscience, Inc. receives funding from Massachusetts Life Science Center
March, 2012 Valerion Therapeutics (formerly 4s3 Bioscience, Inc.) Secures $20M in Series A Financing
February, 2012 Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement Provenance secures $8M project financing for the continued clinical development of the anti-cancer therapeutic, DI-Leu16-IL2.
February, 2012 Alopexx announced today that sanofi-aventis exercises option to acquire exclusive and worldwide rights to Alopexx Pharmaceuticals’ novel human monoclonal antibody targeting infectious diseases

News/Corporate Highlights

April, 2016 The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG
November, 2015 Remission Induction in a Phase I/II Study of an Anti-CD20-Interleukin-2 Immunocytokine DI-Leu16-IL2 in Patients with Relapsed B-Cell Lymphoma
October, 2015 Daniel Fells’ MRSA battle a chilling reminder of infection danger in NFL
June, 2015 Recent results demonstrate PNAG on the surface of both the larval stage (L3) and blood stage (L1) of Dirofilaria immitis, the cause of heart-worm in dogs and cats, raising the possibility that a PNAG vaccine could prevent this mosquito-borne infection in pets.
June, 2015 Valerion Therapeutics Presents On The Development Of A Humanized Antibody Platform At The International Myotonic Dystrophy Consortium Meeting, Paris, France.
November, 2014 Alopexx Pharmaceuticals invited present overview of PNAG technology at the World Health Organization consultation on scientific and regulatory pathways for the development, approval and use of monoclonal antibodies against infectious diseases
February, 2014 Valerion, in collaboration with Genethon and The Institut de Myologie, launches a Natural History and Functional Assessment Study in Patients with Myotubular Myopathy
June, 2013 MTM: MDA Funds Development of Myotubularin-Based Treatment
April, 2013 MDA article on MTM program